Malignant neoplasm, pancreas

Disease

Note: Some component of this panel might be part of the comprehensive metabolic panel.

Note: Rule out cancer of islet cells.

Note: Ruel out liver disease.

Note: EGFR is expressed 30-50% in Pancreatic ductal adenocarcinoma (PDAC). http://www.ncbi.nlm.nih.gov/pubmed/26361407

Note: Not specific for pancreas cancer, but helpful in therapy treatment.

Note: In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.

Note: Alternative to Comprehensive Metabolic Panel.

Note: Alternative to hepatic liver panel.

Note: Early detection of pancreatic cancer.

Note: Chemotherapy monitoring.

Note: Determine therapeutic strategy for cancer therapeutics such as Tegafur.

Note: Rule out gastrointestinal cancer and bleeding.

Note: Adjunctive screening for the early detection of pancreatic cancer in appropriate high-risk populations.

Note: Early detection and interval screening of high-risk individuals for pancreatic cancer.

Note: Early detection of pancreatic cancer.

Note: Please use “Pain Management Pharmacogenetics Gene Variation Panel” if testing ordered for pain management. This panel is comprehensive, and it is general and not specific for pain management.

Note: Used in prognosis of malignancy.

Note: Therapy selection and management.

Note: If iron is low due to anemia.

Note: Therapy monitoring.

Note: If hemoglobin is low due to anemia.

Note: If hemoglobin is low due to anemia.

Note: Aid in the diagnosis and management.

Note: Supportive in diagnosis and treatment.

Note: Supportive in diagnosis and treatment.

Note: Supportive in diagnosis and treatment.

Note: Supportive in diagnosis and treatment.

Note: Therapy selection and monitoring.

Note: Rule out hepatocellular carcinoma.

Note: In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.

Note: In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.

Note: In solid tumors, the presence of an NTRK gene fusion is a biomarker for response to tropomyosin receptor kinase (TRK) inhibitor therapies.

Note: Immunotherapy selection screen.

Note: Alternative to specific genetic markers. Good for therapy selection and monitoring.

Note: Alternative to specif gene markers. Good for therapy selection and monitoring.

Note: Tempus’ PurISTSM test identifies the molecular subtype of patients with unresectable stage III or stage IV pancreatic ductal adenocarcinoma.

Note: IF iron is low due to anemia.

Note: Individual cancer test tissue specific is recommended.

Note: Not covered by Medicare, LCD L39365.